Adial Pharmaceuticals (ADIL) Income from Continuing Operations (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Income from Continuing Operations of 1954422.0 for Q1 2026, up 66.34% sequentially from 5807130.0 in Q3 2025, and up 16.14% YoY from 1682763.51 in Q1 2025.
Adial Pharmaceuticals (ADIL) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Income from Continuing Operations for 10 years, with the latest figure at 1954422.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 16.14% year-over-year to 1954422.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12891984.0 (up 25.73% YoY) and the FY2025 annual result came in at 24397341.0, down 84.86% from the prior year.
- Income from Continuing Operations improved to 1954422.0 in Q1 2026 per ADIL's latest filing, from 5807130.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1347700.0 in Q3 2023 and troughed at 11126661.0 in Q3 2024.
- A 5-year average of 3290264.62 and a median of 2503986.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations plunged 725.6% in 2024, then jumped 64.01% in 2025.
- Over 5 years, Income from Continuing Operations stood at 2549674.0 in 2022, then rose by 25.31% to 1904437.0 in 2023, then gained by 24.21% to 1443297.0 in 2024, then tumbled by 302.35% to 5807130.0 in 2025, then surged by 66.34% to 1954422.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1954422.0, 5807130.0, and 2799755.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | -51.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.95 Mn |
| Sep 30, 2025 | -5.81 Mn |
| Jun 30, 2025 | -2.80 Mn |
| Mar 31, 2025 | -2.33 Mn |
| Dec 31, 2024 | -1.44 Mn |
| Sep 30, 2024 | -11.13 Mn |
| Jun 30, 2024 | -2.46 Mn |
| Mar 31, 2024 | -6.48 Mn |
| Dec 31, 2023 | -1.90 Mn |
| Sep 30, 2023 | -1.35 Mn |
| Jun 30, 2023 | -1.51 Mn |
| Mar 31, 2023 | -2.24 Mn |
| Dec 31, 2022 | -2.55 Mn |
| Sep 30, 2022 | -2.55 Mn |
| Jun 30, 2022 | -3.24 Mn |
| Mar 31, 2022 | -2.91 Mn |
| Dec 31, 2021 | -5.92 Mn |
| Sep 30, 2021 | -4.32 Mn |
| Jun 30, 2021 | -4.44 Mn |
| Mar 31, 2021 | -4.83 Mn |